A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Ramantamig
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC